SEC Company Response from SYNLOGIC, INC. (SYBX) (CIK 0001527599) (SYBX) — Sep 25, 2015
SYNLOGIC, INC. (SYBX) (CIK 0001527599)
Date: Sept. 25, 2015 · CIK: 0001527599 · Accession: 0001104659-15-067370
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-206544
Letter
Mirna Therapeutics, Inc. 2150 Woodward Street, Suite 100 Austin, TX 78744
September 25, 2015
VIA EDGAR AND E-MAIL
United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010
Attention:
Jeffrey P. Riedler, Assistant Director
Tara Keating Brooks
Bryan Pitko
Sasha Parikh
Jim Rosenberg
Re:
Mirna Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333-206544)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-206544) (the “Registration Statement”) of Mirna Therapeutics, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on September 29, 2015, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Mark Roeder at (650) 463-3043.
The Company acknowledges the following:
· should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Thank you for your assistance in this matter.
Very truly yours,
MIRNA THERAPEUTICS, INC.
By:
/s/ Paul Lammers
Paul Lammers, M.D., M.Sc.
President and Chief Executive Officer
CC:
Alan Fuhrman, Mirna Therapeutics, Inc.
Jon Irvin, Mirna Therapeutics, Inc.
Alan C. Mendelson, Esq., Latham & Watkins LLP
Mark V. Roeder, Esq., Latham & Watkins LLP
Thomas Holden, Esq., Ropes & Gray LLP
September 25, 2015
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Mirna Therapeutics, Inc.
Registration Statement on Form S-1 (SEC File No. 333-206544) (the “Registration Statement”)
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Mirna Therapeutics, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Washington, D.C. time, on September 29, 2015 or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed approximately 1,687 copies of the preliminary prospectus dated September 18, 2015 (the “Preliminary Prospectus”) through the date hereof, to underwriters, dealers, institutions and others.
In connection with the Preliminary Prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement as promulgated by Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Citigroup Global Markets Inc.
Show Raw Text
CORRESP 1 filename1.htm Mirna Therapeutics, Inc. 2150 Woodward Street, Suite 100 Austin, TX 78744 September 25, 2015 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jeffrey P. Riedler, Assistant Director Tara Keating Brooks Bryan Pitko Sasha Parikh Jim Rosenberg Re: Mirna Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333-206544) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (File No. 333-206544) (the “Registration Statement”) of Mirna Therapeutics, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on September 29, 2015, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Mark Roeder at (650) 463-3043. The Company acknowledges the following: · should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; · the action of the Commission or the staff, acting pursuant to delegated authority in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and · the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Thank you for your assistance in this matter. Very truly yours, MIRNA THERAPEUTICS, INC. By: /s/ Paul Lammers Paul Lammers, M.D., M.Sc. President and Chief Executive Officer CC: Alan Fuhrman, Mirna Therapeutics, Inc. Jon Irvin, Mirna Therapeutics, Inc. Alan C. Mendelson, Esq., Latham & Watkins LLP Mark V. Roeder, Esq., Latham & Watkins LLP Thomas Holden, Esq., Ropes & Gray LLP September 25, 2015 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Mirna Therapeutics, Inc. Registration Statement on Form S-1 (SEC File No. 333-206544) (the “Registration Statement”) Ladies and Gentlemen: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Mirna Therapeutics, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Washington, D.C. time, on September 29, 2015 or as soon thereafter as practicable. Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed approximately 1,687 copies of the preliminary prospectus dated September 18, 2015 (the “Preliminary Prospectus”) through the date hereof, to underwriters, dealers, institutions and others. In connection with the Preliminary Prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement as promulgated by Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, Citigroup Global Markets Inc. Leerink Partners LLC For themselves and as representatives of the several underwriters By: CITIGROUP GLOBAL MARKETS INC. By: /s/ Jennifer Jarrett Name: Jennifer Jarrett Title: Managing Director By: LEERINK PARTNERS LLC By: /s/ John I. Fitzgerald, Esq. Name: John I. Fitzgerald, Esq. Title: Managing Director [Signature Page to Mirna Therapeutics, Inc. S-1 Acceleration Request]